Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

CEO

ISIN

US80880W2052

WKN

000A412WV

Listings

0 Comments

Share your thoughts

FAQ

What is Scilex Company stock price today?▼

The current price of D8B0.F is €5.65 EUR — it has increased by +5.61% in the past 24 hours. Watch Scilex Company stock price performance more closely on the chart.

What is Scilex Company stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Scilex Company stocks are traded under the ticker D8B0.F.

When is the next Scilex Company earnings date?▼

Scilex Company is going to release the next earnings report on June 03, 2026.

What were Scilex Company earnings last quarter?▼

D8B0.F earnings for the last quarter are -0.4 EUR per share, whereas the estimation was -0.4 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.

When did Scilex Company complete a stock split?▼

Scilex Company has not had any recent stock splits.